Search research articles
Contact Us
Filters
Showing results (161-170 of 195) with videos related to
Page
of 20
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2018
NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263
Anahita Dastur, AHyun Choi, Carlotta Costa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2013
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer
Erin M Coffee, Anthony C Faber, Jatin Roper, et al.
Transgenic Research
|
November 26, 2008
Production of recombinant albumin by a herd of cloned transgenic cattle
Yann Echelard, Jennifer L Williams, Margaret M Destrempes, et al.
Science Translational Medicine
|
May 18, 2018
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma
Timothy L Lochmann, Krista M Powell, Jungoh Ham, et al.
Cancers
|
June 2, 2021
Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA
Carter K Fairchild, Konstantinos V Floros, Sheeba Jacob, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
January 9, 2025
TAK-994 mechanistic investigation into drug-induced liver injury
Tadahiro Shinozawa, Kazumasa Miyamoto, Kevin S Baker, et al.
European Journal of Immunology
|
August 13, 2004
Antibody-mediated activation of the classical pathway of complement may compensate for mannose-binding lectin deficiency
Anja Roos, Peter Garred, Manon E Wildenberg, et al.
Cancer Research
|
September 23, 2024
The Innate Immune System and the TRAIL-Bcl-XL Axis Mediate a Sex Bias in Lung Cancer and Confer a Therapeutic Vulnerability in Females
Lauren May, Bin Hu, Preksha Jerajani, et al.
Science Translational Medicine
|
August 2, 2013
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma
Ryan B Corcoran, Stephen Michael Rothenberg, Aaron N Hata, et al.
Cell Reports
|
July 29, 2022
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition
Jinyang Cai, Sheeba Jacob, Richard Kurupi, et al.
Page
of 20
Search research articles
Search
Showing results (161-170 of 195) with videos related to
Sort By:
Page
of 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2018
NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263
Anahita Dastur, AHyun Choi, Carlotta Costa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 4, 2013
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer
Erin M Coffee, Anthony C Faber, Jatin Roper, et al.
Transgenic Research
|
November 26, 2008
Production of recombinant albumin by a herd of cloned transgenic cattle
Yann Echelard, Jennifer L Williams, Margaret M Destrempes, et al.
Science Translational Medicine
|
May 18, 2018
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma
Timothy L Lochmann, Krista M Powell, Jungoh Ham, et al.
Cancers
|
June 2, 2021
Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA
Carter K Fairchild, Konstantinos V Floros, Sheeba Jacob, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
January 9, 2025
TAK-994 mechanistic investigation into drug-induced liver injury
Tadahiro Shinozawa, Kazumasa Miyamoto, Kevin S Baker, et al.
European Journal of Immunology
|
August 13, 2004
Antibody-mediated activation of the classical pathway of complement may compensate for mannose-binding lectin deficiency
Anja Roos, Peter Garred, Manon E Wildenberg, et al.
Cancer Research
|
September 23, 2024
The Innate Immune System and the TRAIL-Bcl-XL Axis Mediate a Sex Bias in Lung Cancer and Confer a Therapeutic Vulnerability in Females
Lauren May, Bin Hu, Preksha Jerajani, et al.
Science Translational Medicine
|
August 2, 2013
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma
Ryan B Corcoran, Stephen Michael Rothenberg, Aaron N Hata, et al.
Cell Reports
|
July 29, 2022
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition
Jinyang Cai, Sheeba Jacob, Richard Kurupi, et al.
Page
of 20